Bioatla

Bioatla ROE

The Return on Equity (ROE) of Bioatla (BCAB) as of Nov 18, 2026 is 164.71 %. In the previous year, Return on Equity (ROE) was -489.14 % — a change of -133.67% (higher).

ROE

164.71 %

YoY

-133.67%

Last updated:

In 2025, Bioatla's return on equity (ROE) was 164.71 %, a -133.67% increase from the -489.14 % ROE in the previous year.

The Bioatla ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
101.81 USD
Jan 1, 2019
53.24 USD
Jan 1, 2020
-17.07 USD
Jan 1, 2021
-45.25 USD
Jan 1, 2022
-58.38 USD
Jan 1, 2023
-174.70 USD
Jan 1, 2024
-489.14 USD
Jan 1, 2025
164.71 USD
The Bioatla ROE history
YEARROEYoY
164.71 %-133.67%
-489.14 %+179.99%
-174.70 %+199.24%
-58.38 %+29.01%
-45.25 %+165.02%
-17.07 %-132.07%
53.24 %-47.71%
101.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

ROE Details

Decoding Bioatla's Return on Equity (ROE)

Bioatla's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Bioatla's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Bioatla's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Bioatla’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Bioatla stock

Return on Equity (ROE) of Bioatla is 164.71 % in 2025.

Return on Equity (ROE) of Bioatla changed from -489.14 % to 164.71 %, representing a -133.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Bioatla since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Bioatla with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bioatla

All Key Metrics — Bioatla